drugset / Trial / NCT00266214

Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome

NCT00266214 ↗

Phase 3 Terminated 210 enrolled Endo USA Inc., a Keenova Therapeutics Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the analgesic efficacy and safety of the lidocaine patch 5% compared to placebo in patients with moderate to severe pain associated with carpal tunnel syndrome.

Timeline

Start
2005-11
Primary completion
2007-01
Completion
2007-01

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified 5 % Topical